8 Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial
8. 纳武利尤单抗联合伊匹木单抗对比舒尼替尼一线治疗晚期肾细胞癌:来自3期CheckMate 214试验的8年随访及对预后良好患者的分析
期刊:Oncologist
影响因子:4.2
doi:10.1093/oncolo/oyaf354
Brar, Gagandeep; Kasi, Pashtoon Murtaza; Saliby, Renee Maria; Xie, Wanling; Wells, Connor J; Saad, Eddy; Eid, Marc; Semaan, Karl; Labaki, Chris; Ferrier, Evan; Zarba, Martin; Ebrahimi, Hedyeh; Ravi, Praful; Suarez, Cristina; Morales, Jose Ruiz; McKay, Rana R; Powles, Thomas; Wood, Lori; Lalani, Aly-Khan A; Pal, Sumanta K; de Velasco, Guillermo; Takemura, Kosuke; Agarwal, Neeraj; Braun, David A; Heng, Daniel Y; Choueiri, Toni K; Atkins, Michael B; Escudier, Bernard; McDermott, David F; Burotto, Mauricio; Choueiri, Toni K; Hammers, Hans J; Plimack, Elizabeth R; Porta, Camillo; George, Saby; Powles, Thomas; Donskov, Frede; Kollmannsberger, Christian K; Grimm, Marc-Oliver; Tomita, Yoshihiko; Rini, Brian I; Jiang, Ruiyun; Federov, Viktor; Lee, Chung-Wei; Desilva, Heshani; Tannir, Nizar M; Motzer, Robert J